RxDoctor Payments Data

Darshan Patel, MD

Hospitalist · Homer, NYNPI 1962662957

Payments from drug & device makers

$1,576in general payments, 2019–2025

Across 35 payments — averaging $45.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$394
  • AbbVie$380
  • Edwards Lifesciences$157
  • Chiesi USA, Inc.$141
  • Alkermes, Inc.$138
  • Gilead$125
  • plus $240 from 4 others

What the payments were for

  • Food & beverage$1,576100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,576 in reported general payments places this provider in the 90th percentile of 1,860 hospitalist providers in New York.

See all hospitalist providers in New York

Medicare billing

Part B allowed, 2024
$120,185
Medicare patients
276
Services billed
1,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate24$59,179
EliquisApixaban149$49,622
XareltoRivaroxaban116$33,700
RexultiBrexpiprazole24$13,344
NamzaricMemantine Hcl/Donepezil Hcl26$7,710
Breo ElliptaFluticasone/Vilanterol17$7,406
MyrbetriqMirabegron21$5,360
Advair HfaFluticasone Propion/Salmeterol11$5,148
JanuviaSitagliptin Phosphate12$3,876
EntrestoSacubitril/Valsartan14$3,122
BelsomraSuvorexant14$2,813
Carbidopa-LevodopaCarbidopa/Levodopa85$2,718
Carbamazepine43$2,335
Memantine Hcl33$2,304
Aripiprazole15$2,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$394$33,700116 claims
Otsuka America Pharmaceutical, Inc.Rexulti$48$13,34424 claims
AbbVieNamzaric$380$7,71026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,860 hospitalist providers in New York.

Other hospitalist in Homer

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →